Leading Cross-Functional Teams from Concept to Commercialization with Marwan Fathallah

What It Covers

Marwan Fathallah, CEO of DIA Global with 30 years in life sciences, outlines the leadership framework required to move products from concept to commercialization, covering cross-functional team structure, daily management cadence, KPI design, conflict resolution, and the cultural balance between innovation and regulatory rigor.

Key Questions Answered

• •Cross-Functional Integration: Embed regulatory, marketing, clinical, and R&D stakeholders into the product development process from day one rather than treating compliance as a final gate. When these disciplines coexist early, they calibrate each other's risk tolerance, accelerating both innovation and submission readiness without sacrificing scientific rigor or safety standards.
• •Project Room Cadence: Structure cross-functional teams around a physical or virtual project room with daily stand-up meetings where each function reports KPI status — on track or off track — against a visible timeline. The project manager acts as an independent Maestro, not embedded in any single function, to maintain neutrality and accountability across all stakeholders.
• •Leading Indicator KPIs: Avoid single long-horizon KPIs like "complete verification and validation." Instead, map milestone-based leading indicators — feasibility test results, dry-run clinical study completion — that signal trajectory toward the final goal. Without these intermediate markers, risk goes unmanaged and teams face avoidable late-stage surprises that compress timelines and inflate costs.
• •Conflict Resolution Protocol: Address disruptive team dynamics immediately and privately using observation-based language — "I am seeing" rather than accusatory framing — which prevents debate about intent. If behavior persists, escalate to the function head framed as a check-in rather than a complaint, then surface team dynamics formally in the weekly leadership update with proposed options.
• •Systems Thinking Over Silos: Train team members to understand product development as an interdependent system where delaying a regulatory submission to incorporate stronger clinical data may increase approval probability despite disrupting the business plan. Leaders who have held roles across the full development cycle from concept to post-market are measurably less defensive and more effective at these trade-off decisions.